XE9 Stock Chart & Stats
€10.10
€0.40(1.79%)
At close: 4:00 PM EST
€10.10
€0.40(1.79%)
Day’s Range― - ―
52-Week Range€5.60 - €17.70
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€1.27B
Enterprise Value€637.69
Total Cash (Recent Filing)€444.95M
Total Debt (Recent Filing)€175.16M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 05, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding74,141,594
10 Day Avg. Volume10
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.17Price Target Upside109.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.4
Revenue Forecast (FY)€63.68M
Bulls Say, Bears Say
Bulls Say
Proprietary Engineering PlatformXencor’s XmAb and Xtend Fc engineering form a durable competitive asset: engineered Fc and bispecific capabilities can support differentiated biologics across oncology and immunology. Sustained platform leverage enables multiple programs and partner deals, reducing single-product dependence if clinical progress continues.
Manageable LeverageRelatively low debt provides financial flexibility to fund R&D and clinical programs without immediate debt servicing pressure. This balance-sheet room supports multi-cycle clinical development and potential partnering or opportunistic financing without severely constraining operating choices over the next several quarters.
Governance And Retention SupportBoard and shareholder actions to expand equity incentives and affirm compensation indicate governance alignment to retain scientific and commercial leadership. Strong retention mechanisms reduce execution risk across long development timelines and help preserve institutional knowledge during critical Phase 2/3 programs.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicate material funding needs to support clinical programs. Persistent cash burn raises dilution or financing risk and can force timing-sensitive strategic decisions, making long-term program continuity dependent on external capital or partner milestone receipts.
Declining Revenue And Large LossesFalling revenue and outsized net losses reflect that operating spend and R&D still far outstrip earned collaboration income. This structural imbalance pressures returns and requires successful clinical readouts or new partnership milestones to reverse negative profitability trends over the medium term.
Revenue Concentration And Milestone DependenceAs a clinical-stage biotech, Xencor’s revenue model depends on partner upfronts, milestones and future royalties. That creates lumpiness and execution-linked cash flows; absent commercial products, sustainable revenue hinges on external program success and deal flow, increasing structural funding sensitivity.
Xencor News
XE9 FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was €5.60 and its highest was €17.70 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is €1.27B.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on May 06, 2026. The company reported -€1.502 earnings per share for the quarter, missing the consensus estimate of -€0.728 by -€0.774.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.7.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 74,141,594 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -€1.502 in its last earnings report, missing expectations of -€0.728. Following the earnings report the stock price went down -6.481%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in DE:XE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.17 (109.57% Upside)
€21.17 (109.57% Upside)
Blogger Sentiment
Bullish
DE:XE9 Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XE9 Stock 12 Month Forecast
Average Price Target
€21.17
▲(109.57% Upside)
Technical Analysis
Dianthus Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
Relay Therapeutics
―
Maravai Lifesciences Holdings
―